aTyr Pharma (NASDAQ:ATYR) Trading Down 8.9% - Here's What Happened

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report)'s stock price dropped 8.9% during mid-day trading on Thursday . The stock traded as low as $5.94 and last traded at $6.02. Approximately 3,340,882 shares were traded during trading, an increase of 61% from the average daily volume of 2,080,213 shares. The stock had previously closed at $6.61.

Wall Street Analyst Weigh In

ATYR has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wells Fargo & Company upped their target price on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $20.20.

aTyr Pharma Stock Up 5.0%

The business has a fifty day moving average price of $5.08 and a two-hundred day moving average price of $4.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The firm has a market capitalization of $518.87 million, a price-to-earnings ratio of -7.20 and a beta of 0.89.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its position in aTyr Pharma by 46.0% during the first quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company's stock worth $1,155,000 after purchasing an additional 120,496 shares in the last quarter. Octagon Capital Advisors LP boosted its position in aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after purchasing an additional 2,652,000 shares in the last quarter. Millennium Management LLC boosted its position in aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock worth $4,829,000 after purchasing an additional 1,231,052 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in aTyr Pharma by 11.0% during the first quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock worth $2,347,000 after purchasing an additional 77,290 shares in the last quarter. Finally, MAI Capital Management boosted its position in aTyr Pharma by 306,100.0% during the first quarter. MAI Capital Management now owns 658,330 shares of the company's stock worth $1,988,000 after purchasing an additional 658,115 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.